Going-concern and financing risk
The company needs external capital to fund operations and commercialization before meaningful revenue is established.
- Scope
- Corporate liquidity and business continuity
- Materiality
- high
Regenerex Pharma, Inc.
Regenerex Pharma, Inc. is a U.S.-based pharmaceutical preparations company focused on advanced wound care healing products. Its business centers on proprietary wound-closure technologies, including QBx™, for chronic, acute, and contamination-controlled wound treatment across medical care settings.
0.13
0.13
| % | |
|---|---|
| Advanced wound care technologies | 45% Proprietary technologies and formulations for chronic, acute, and contaminated wounds. |
| Wound Closure System protocols | 20% Clinical protocols and treatment pathways used with the company's wound products. |
| QBx™ active ingredient platform | 20% Core biologic ingredient designed to down-regulate proteases and support healing. |
| Digital wound management tools | 10% AI-enabled patient tracking and medication support software for wound care programs. |
| Distribution and commercialization services | 5% Partner-led commercialization, distributor development, and market access support. |
Regenerex sells into healthcare payors and care-delivery organizations that manage chronic and acute wounds, especially...
- State Medicaid programsprimary
Buy wound care products and protocols to manage high-cost chronic wound populations at lower total cost.
- Home health and nursing homesprimary
Use wound closure products for aging patients with diabetic, pressure, and venous ulcers.
- Private insurance networkssecondary
Seek preferred-provider arrangements and reimbursable wound care solutions that improve outcomes.
- Government healthcare systemssecondary
Includes VA and correctional facilities that need standardized wound protocols and cost control.
- International distributorsemerging
Purchase or distribute the company's products in Asia and the Middle East.
Regenerex is headquartered in Tennessee and also maintains an office in Nevada, with operations organized around U.S...
- •Headquartered in Gordonsville, Tennessee
- •Identity office in Las Vegas, Nevada
- •U.S. Southeast is a key target for Medicaid contracts
- •Puerto Rico is discussed for federally funded programs
- •Asia and the Middle East are target export markets
- •Manufacturing and distribution are largely outsourced
Regenerex is focused on converting its wound-care technologies into reimbursable contracts with state Medicaid...
01
Win reimbursement-backed U.S. contractsshort-term
The business depends on payor access and contracted patient volume to commercialize wound products.
02
Build international distributionmedium-term
Distributor-led expansion can extend the addressable market without heavy owned infrastructure.
03
Differentiate through technology and datamedium-term
Clinical protocols and AI tools can support adoption, adherence, and reimbursement value.
Regenerex is a development-stage healthcare company with no established revenue base, so execution depends on winning...
Reimbursement and payor access risk
The business model relies on Medicaid, Medicare, and insurer coverage for wound-care adoption.
- Scope
- U.S. state programs, private insurance, federal programs
- Materiality
- high
Commercialization and adoption risk
Healthcare buyers may be slow to adopt new wound-care protocols without strong clinical and economic proof.
- Scope
- Hospitals, home health, nursing homes, clinics
- Materiality
- high
Cybersecurity and cash theft risk
A reported bank-account hacking incident shows exposure to fraud and treasury controls.
- Scope
- Cash management
- Materiality
- high
Competition risk
The company competes with established wound-care and consumer product companies with scale and distribution.
- Scope
- Domestic and international wound-care markets
- Materiality
- medium
Stock-based compensation and warrants
Expense recognition and equity dilution
Purchased intellectual property
Balance sheet carrying value and amortization
Going-concern assessment
Disclosure and investor risk assessment
Lease accounting
Right-of-use assets and lease liabilities
RenovoRx, Inc.
RNXT · Pharmaceutical Preparations
BIOREGENX, INC.
BRGX · Services-Computer Programming, Data Processing, Etc.
Neuraxis, INC
NRXS · Electromedical & Electrotherapeutic Apparatus
Neuraxis, INC is a U.S.-based medical device company focused on neuromodulation therapies for pediatric and adult patients.
Amylyx Pharmaceuticals, Inc.
AMLX · Pharmaceutical Preparations
REGENERON PHARMACEUTICALS, INC.
REGN · Pharmaceutical Preparations
Regeneron Pharmaceuticals is a U.S.-based biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases.
MANGOCEUTICALS, INC.
MGRX · Services-Misc Health & Allied Services, NEC
: 29.4.2026